字号·· | 护眼
彭博社

金佰利发行债券,为收购泰诺生产商提供资金Kimberly-Clark Offers Bonds to Help Fund Tylenol Maker Takeover

点「原文对照」整页切到原文,或双击某段只看那段的原文。

Kenvue公司的泰诺品牌止痛药。摄影师:迈克尔·纳格尔/彭博社Kenvue Inc. Tylenol brand pain reliever medication. Photographer: Michael Nagle/Bloomberg

科尔巴士公司正在发行最多五部分的投资级债券,以帮助为其即将进行的收购泰诺生产商Kenvue Inc.提供资金。

Corp. is selling investment-grade bonds in as many as five parts to help fund its pending acquisition of Tylenol maker Kenvue Inc.

根据知情人士透露,该消费品公司正在发行最多五部分的票据,期限为两年至十年,该人士因细节属私人信息而要求匿名。该人士补充称,最长期限票据的初始定价讨论涉及较国债高出约一个百分点的溢价。

The consumer-goods company is offering notes in as many as five parts with maturities of two to 10 years, according to a person with knowledge of the matter, who asked not to be identified because the details are private. Initial price discussions for the longest tenor involve a premium of about one percentage point above Treasuries, the person added.

科尔巴士公司于周五举行了投资者电话会议,当时市场正处于动荡时期。由于通胀数据强于预期导致国债收益率剧烈波动,以及人们对人工智能交易的担忧,众多公司上周推迟了高等级债券发行。

Kimberly-Clark held investor calls on Friday, amid a turbulent period for markets. Numerous companies held off on bringing high-grade bond sales last week as Treasury yields swung sharply on stronger-than-expected inflation data and worries about the artificial-intelligence trade.

科乐氏(Kleenex)制造商的第三季度报告将于11月5日发布。公司通常不会在披露业绩前大约两周的时间内发行债券。

The Kleenex maker’s third-quarter report is due on Nov. 5. Companies typically don’t issue bonds in the roughly two-week period before disclosing results.

摩根大通公司(JPMorgan Chase & Co.)去年晚些时候提供了77亿美元的桥梁融资,以帮助资助此次收购。债券发行预计将取代这一临时借款安排。知情人士表示,其他参与管理此次债券发行的银行包括花旗集团(Citigroup Inc.)和摩根士丹利(Morgan Stanley)。

JPMorgan Chase & Co. provided $7.7 billion in bridge financing late last year to help fund the acquisition. The bond sale is expected to replace that temporary borrowing facility. Other banks managing the bond sale are Citigroup Inc. and Morgan Stanley, the person said.

该以股票为主的收购预计将在年底前完成,目前估值约为360亿美元。科尔巴士公司此前曾表示,补偿方案将包括67亿美元的现金,其中部分将来自新发行的债务。

The largely-stock acquisition, expected to close by the end of the year, is currently valued at about $36 billion. Compensation is set to include $6.7 billion of cash that would in part come from new debt sales, Kimberly-Clark has previously said.

Kenvue自2023年从强生公司(Johnson & Johnson)分拆以来一直面临财务困境,去年该公司还因其最大产品泰诺的安全问题与特朗普政府发生争执。其产品组合还包括妮维雅(Neutrogena)润肤露、李施德林(Listerine)漱口水、苯海拉明(Benadryl)过敏药以及创可贴(Band-Aid)伤口护理产品。

Kenvue has struggled financially since being spun off from Johnson & Johnson in 2023, and the company found itself battling with the Trump administration last year over the safety of its biggest product, Tylenol. Its portfolio also includes Neutrogena lotion, Listerine mouthwash, Benadryl allergy medicine and Band-Aid wound care products.

金佰利克拉克公司去年宣布此次合并时表示,收购肯维将创造一家年收入达320亿美元的公司,使其能够超越联合利华公司,成为仅次于宝洁公司的全球第二大健康与保健产品销售商。

Kimberly-Clark said when the combination was announced last year that buying Kenvue would create a company with $32 billion in revenue and allow it to surpass Unilever Plc to become the second-biggest seller of health and wellness products after Procter & Gamble Co.

阅读媒体原文 ↗